Undisclosed Antibody Programs

About New Paradigm Biosciences

Founded in 2019 and based in Acton, Massachusetts, New Paradigm Biosciences is a private, pre-clinical stage biotech focused on the intersection of AI/machine learning and drug discovery within immuno-oncology. The company's central innovation is a humanized mouse platform designed to overcome a major limitation in immunotherapy development: the poor predictive power of traditional animal models for human immune responses. By engrafting human tumors and immune cells into mice, NPB aims to discover and validate therapeutic antibodies against human-exclusive pathways, potentially unlocking new classes of more effective and targeted cancer treatments.

About MLAB Biosciences

MLAB Biosciences is a private, pre-clinical stage biotech founded in 2016 and based in San Diego, California. The company's core asset is the DIRECT™ (Display Integrated Rational Engineering for the Creation of Therapeutics) platform, an antibody discovery and engineering engine designed to generate novel biologics. With a leadership team and advisory board featuring prominent neuromuscular disease experts, MLAB is positioned to tackle challenging targets in muscular dystrophy and beyond, though it remains in the early, pre-revenue stage of development.

About Ailux Biologics

Ailux Biologics is a private, pre-clinical stage biotechnology company founded in 2020, leveraging an end-to-end AI platform for biologics discovery and design. Its core asset is the AtlaX™ multi-modal biologics database, which powers three foundational AI models to generate and optimize therapeutic candidates, with a pipeline focused on antibody-based therapies for hard-to-treat conditions. The company has established significant validation through strategic collaborations with major pharmaceutical firms like Eli Lilly, UCB, and Janssen Biotech, positioning it as a promising player in the AI-driven drug discovery space.

Therapeutic Areas

Other Cancer (Solid Tumors) Drugs